Etoricoxib vs. Diclofenac in OA
This study has been completed.
Information provided by:
First received: October 5, 2007
Last updated: September 23, 2009
Last verified: September 2009
To compare the safety and tolerability of etoricoxib and diclofenac sodium in the treatment of osteoarthritis of the knee or hip during a six week period.
Drug: MK0663, etoricoxib / Duration of Treatment: 6 Weeks
Drug: Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Etoricoxib 60 mg and Diclofenac Sodium 150 mg in Patient With Osteoarthritis of the Knee or Hip|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Merck:
Primary Outcome Measures:
- This study will assess the effectiveness of the study drug vs. a comparator to treat successfully OA-related joint pain (judged by WOMAC pain subscale).
Secondary Outcome Measures:
- The study drug will be safe and well tolerated during the course of the study.
|Study Start Date:||May 2002|
|Study Completion Date:||December 2002|
Contacts and Locations